

Special Issue

Target-Specific Delivery of Gold and Ruthenium Complex to Cancer Cells: Where Are We?

Message from the Guest Editors

Cancer is the second leading cause of death worldwide, and it is expected that in 20 years, there will be ~26 million new cancer cases. Despite the progress made in the last few years, cancer treatment, mainly focused on radiation therapy and chemotherapy, presents low therapeutic indices and a wide spectrum of severe side-effects, in part due to the little or no selectivity of drugs for cancer cells over nontumoral cells. Therefore, the need for alternative therapeutic options with improved selectivity is critical. Following the clinical success achieved with platinum complexes, the search for metallodrugs with improved therapeutic properties has been extremely active within the bioinorganic/organometallic chemistry community. Among the large number of metal complexes with considerable anticancer properties, gold and ruthenium complexes are amongst the most promising alternatives. Nevertheless, this topic still remains a challenge to all scientists, especially those involved in the design of innovative metal-based target specific agents. We welcome submissions dealing with advancements and challenges of metallodrug discovery for cancer treatment.

Guest Editors

Dr. Tânia S. Morais

Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, 1749-016 Lisboa, Portugal

Dr. João D. G. Correia

Departamento de Engenharia e Ciências Nucleares and Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, Estrada Nacional 10 (Km 139,7), 2695-066 Bobadela LRS, Portugal

Deadline for manuscript submissions

closed (31 May 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/119000

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).